Researchers at Children's Hospital of Philadelphia (CHOP) reported today that adolescents with hypertrophic cardiomyopathy (HCM) who took mavacamten experienced reduced obstruction, allowing blood to ...

New data support the use of mavacamten as a treatment option for adolescents with symptomatic obstructive hypertrophic cardiomyopathy, researchers reported at the American College of Cardiology ...

BMS Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos in Adolescents with Symptomatic oHCM ...

Mavacamten, an investigational allosteric modulator of cardiac myosin, has proved superior to placebo for improving symptoms and reducing or eliminating obstruction of the left ventricle in patients ...

Treatment with aficamten significantly improved exercise capacity compared with placebo. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for aficamten for ...

Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

The physical symptoms of obstructive hypertrophic cardiomyopathy (HCM) are very real, ranging from chest pain and shortness of breath to a racing heart, lightheadedness, and fatigue. But there’s also ...

In a move greatly welcomed by heart charities, the National Institute for Health and Care Excellence (NICE) has approved mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten (MyoKardia) is a novel, oral, allosteric modulator of cardiac myosin. This therapy was specifically ...